Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
13.80
-0.04 (-0.29%)
Aug 8, 2022 4:00 PM EDT - Market closed

Balance Sheet (Quarterly)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Quarter Ended 2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Cash & Equivalents
55.9536.439.39251.6370.777.81---0.66
Short-Term Investments
306.07339.38348.12142.5700---0
Cash & Cash Equivalents
362.02375.78387.51394.270.777.810000.66
Cash Growth
411.55%4709.69%---1087.39%----
Receivables
0000.380.388---0
Other Current Assets
2.641.242.082.040.260.25---0
Total Current Assets
364.65377.02389.59396.6171.4116.06---0.66
Property, Plant & Equipment
2.791.61.360.220.160.16---0.02
Other Long-Term Assets
1.151.210.1400.260---0
Total Long-Term Assets
3.942.811.50.220.410.16---0.02
Total Assets
368.6379.82391.08396.8271.8216.22---0.68
Accounts Payable
1.942.463.610.350.860.43---0.27
Deferred Revenue
4.655.867.17.8988---0
Current Debt
0.150.190.21000---4
Other Current Liabilities
5.774.281.540.96-1.96-5.25---0.36
Total Current Liabilities
12.5212.812.479.216.893.18---4.63
Long-Term Debt
000.02000---0
Other Long-Term Liabilities
-0.71.842.824.356.05----
Total Long-Term Liabilities
00.71.862.824.356.05---0
Total Liabilities
12.5213.514.3312.0311.249.23---4.63
Total Debt
0.150.190.24000---4
Common Stock
418.47414.01410.72408.010.250.10000.01
Retained Earnings
-60.82-47.41-34-23.23-17.02-14.74----7.96
Comprehensive Income
-1.57-0.270.020.0200---0
Shareholders' Equity
356.08366.33376.75384.8-16.77-14.64----7.94
Total Liabilities and Equity
368.6379.82391.08396.82-5.53-5.41000-3.32
Net Cash / Debt
361.86375.59387.27394.270.777.81000-3.34
Net Cash / Debt Growth
411.33%4707.21%--------
Net Cash Per Share
8.7615.969.4139.2963.697.78----4.99
Working Capital
352.14364.22377.12387.464.5112.88----3.97
Book Value Per Share
8.6215.579.1638.35-15.09-14.58----11.87
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).